Second, osimertinib has been approved as the first‐line treatment for advanced EGFR‐mutant lung cancer, but the study was conducted prior to its reimbursement by the National Health Insurance in Taiwan; thus, we only had three first‐line osimertinib‐treated patients (two with paired tissue and liquid NGS and one with liquid NGS only). This evidence concerns the gene EGFR and lung cancer.